Home > News > BIT’s 5th Aniversary of Protein and Peptide Conference (March 23-25,2012)
Industry Updates New Products Supplier News Upcoming Events business web

BIT’s 5th Aniversary of Protein and Peptide Conference (March 23-25,2012)

Hits:4661   Date: 12/15/2011

BIT's 5th Aniversary of Protein and Peptide Conference

BIT’s 5th Aniversary of Protein and Peptide Conference
Theme: Powerful Proteins and Peptides
 March 23-25,2012 |  Beijing, China
 
Invitation Letter
 
Dear Sirs or Madams,
 
BIT Life Sciences is proud to present the 5th Anniversary of Protein and Peptide Conference (PepCon‐2012) with a theme of “Powerful  Proteins  and  Peptides”.  The  5th  PepCon‐2012  to  be  held  during  March  23‐25,  2012,  Beijing,  China  will  offer professionals in fields of protein and peptide a multidisciplinary informative platform. Based upon your great contributions to  this  particular  field,  the  organizing  committee  cordially  invites  you  to  Chair    a  session  you  are  most  interested  in  the congress.  
 
The  annual  congress  PepCon  initiated  by  BIT  Life  Sciences  in  2003  has  become  accepted  as  an  influential  conference  for worldwide protein and peptide professionals to discuss and develop the latest research breakthroughs as well as potential business opportunities. For PepCon‐2011, more than 800 participants and 80 exhibitors from 48 countries have joined the conference  and  made  the  best  out  of  it.  This  year  we  will  manage  to  provide  an  even  better  platform  for  information exchange and business collaborations after 5 years of successful running of PepCon. The website at: http://www.bitlifesciences.com/pepcon2012/   
 
We look forward to seeing you in Beijing in 2012 for this influential event.
 
Sincerely yours,
 
Dr. Xiaodan Mei
Executive Chair
Organizing Committee of PepCon‐2012
East Area, F11, Building 1,   Dalian Ascendas IT Park,   1 Hui Xian Yuan,
Dalian Hi‐tech Industrial Zone, LN 116025, China
 
Contact: Ms. Sally Guo,

Tel: 0086‐411‐8479609‐801 Fax: 0086‐411‐84799629
E‐mail:
sally@bitlifesciences.com  

A World’s Leading Meeting Place for Protein/Peptide Sciences!
 
Highlights of the Conference  
 
    •   500+ presentations in the areas of science, technology and business  
    •   200+ scientific posters presenting exciting new research achievements  
    •   100+ exhibition booths showcasing new products and technologies  
    •   2000+  attendees  coming  from  all  over  the  world  to  exchange  ideas,  build  new  networks,  and foster friendships  
    •   5+  concurrent  conferences  focus  on  frontier  technologies  of  protein,  peptide,  antibody,  and vaccine  
    •   The most professional scientific instrument and laboratory equipment exhibition in China   
    •   Tech‐tours to Beijing, Xi’an, Hangzhou, Tibet and Kunming, China

Renowned Speakers
 
Dr. Mathias Uhlén, Professor, Royal Institute of Technology (KTH), Sweden
Dr. Juergen Engel, President & CEO, Aeterna Zentaris, Germany
Dr. Thomas M. Li, Senior Director, Technology Management, CTO, USA and Head of Asia Pacific Technology Management, Roche, Singapore
Dr. Vadim T. Ivanov, Professor, member of Russia Academic of Sciences, Russia
Dr. G.M. Crippen, Professor, College of Pharmacy, University of Michigan, USA
Dr. Samir Hanash, Professor, University of Michigan, USA
Dr. Albert Ahn, President, AB Science, USA
Dr. Wolfgang Baumeister, Professor, Max-Planck-Institute of Biochemistry, Germany
Dr. Chung Hsuan (Winston) Chen, Distinguished Research Fellow & Director, The Genomics Research Center, Academia Sinica, Taiwan
Dr. Dave Litchfield, Professor and Chair, University of Western Ontario, Canada
Dr. Marc Wilkins, Professor, University of New South Wales, Australia
Dr. Lorenz Mayr, Executive Director, Unit Head Biology, Protease Platform, Novartis Pharma AG / NIBR, Switzerland
Dr. Peter W. Schiller, Professor of Pharmacology, Director, Laboratory of Chemical Biology and Peptide Research, Clinical Research Institute of Montreal, Canada
Dr. Kirsten Jung, Professor, Ludwig-Maximilians-Universitaet Muenchen, Germany
Dr. Acevedo-Duncan Mildred Enid, Research Associate Professor, Department of Chemistry, University of South Florida, USA 

Scientific Program
 
Part 1: Protein Sciences and Technology 
Chapter 1: Frontier of Protein Sciences and Technology

Section 1‐1: Breaking Research in Protein Science
Session 1‐1‐1: System Biology and Protein Discovery
Session 1‐1‐2: Protein Biogenesis, Protein Synthesis, and Translational Control
Session 1‐1‐3: Protein Folding and Misfolding
Session 1‐1‐4: Protein Dynamics and Implications
Session 1‐1‐5: C‐Reactive Proteins
Session 1‐1‐6: Protein Motors
Session 1‐1‐7: Ubiquitin Systems and Protein Degradation
Session 1‐1‐8: Evolution of Protein Families
Session 1‐1‐9: Large Cellular Assemblies
Session 1‐1‐10: Protein Aggregation and Amyloidogenesis
Section 1‐2: Protein Structure and Characterization
Session 1‐2‐1: Protein Structural Biology and Biophysics
Session 1‐2‐2: NMR and Crystallography for Protein Structural Characterization
Session 1‐2‐3: Proteins Interacting with DNA and RNA
Session 1‐2‐4: Computer Modeling for Protein Structural Stability
Session 1‐2‐5: Predictive Computation on Protein Aggregation and Immunogenicity
Session 1‐2‐6: Protein Structure and Characterization
Session 1‐2‐7: Methods and Applications for Protein Design:
Session 1‐2‐8: The Hydrogen Bond and Hydrophobicity and Implications
Session 1‐2‐9: Mapping Physical Protein Interaction Networks
Section 1‐3: Cellular Functions
Session 1‐3‐1: Membrane Proteins, Receptors and Signaling
Session 1‐3‐2: Protein‐protein Interactions and Protein‐transduction

Session 1‐3‐3: Protein Post‐translational Modification and Activity Regulation
Session 1‐3‐4: Protein Biosynthesis
Session 1‐3‐5: Protein Trafficking/ Transport/ Translocation, Assembly
Session 1‐3‐6: Cell Signaling Regulation and Ligand binding
Session 1‐3‐7: Cell Cycle Control Proteins
Session 1‐3‐8: Proteins involved in Apoptosis
Session 1‐3‐9: Protein Modifications and Metabolism
Section 1‐4: Novel Protein Study Methods
Session 1‐4‐1: Protein Cellular Localization
Session 1‐4‐2: Bioinformatics for Protein Studies
Session 1‐4‐3: Novel Protein Purification Methods
Session 1‐4‐4: High‐throughput Protein Sequencing
Session 1‐4‐5: Allosteric Control and Conformational Changes
Session 1‐4‐6: The Evolution of Protein Phosphorylation
Session 1‐4‐7: NMR, EM and X‐Ray Crystallography
Session 1‐4‐8: Visualization of Proteins in the Cell
Session 1‐4‐9: Protein Screening and Bioassay
Session 1‐4‐10: Protein Chips, Microfluidics, Arrays and Protein Structures in silico

Chapter 2: Proteomics and Metaproteomics  

Section 2‐1: Innovative Proteome Technologies
Section 2‐2: Bioinformatics and Proteomics and Metaproteomics
Section 2‐3: Animal Models in Proteomics
Section 2‐4: Nanoproteomics, Chip and Array Technologies in Proteomics
Section 2‐5: MS, Imaging MS and MALDI‐TOF in Cancer Proteomics
Section 2‐6: Cancer Proteomics
Section 2‐7: Human Proteome Technologies and Cancer Research
Section 2‐8: Metalloproteomics
Section 2‐9: Neuroproteomics
Section 2‐10: Plant Proteomic
Section 2‐11: Functional and Structural Proteomics of Glycoproteins
Section 2‐12: Metaproteomics of Natural Microbial Communities
Section 2‐13: Oral Metaproteomics and Clinical Significance
Section 2‐14: Gut/GI Tract Microbiota and Metaproteomics
Section 2‐15: Metaproteomics and Novel Enzyme Discovery

Chapter 3: Human Diseases and Protein Discovery

Section 3‐1: Protein Networks in Disease
Section 3‐2: Protein‐protein Interactions and Diseases
Section 3‐3: Protein Misfolding and Human Diseases
Section 3‐4: Protein Folds in Infectious Diseases
Section 3‐5: Intrinsically Disordered Proteins
Section 3‐6: Protein Misfolding and Neurodiseases
Section 3‐7: Proteins in Apoptosis and Autophagy
Section 3‐8: Signal Transductions and Diseases
Section 3‐9: Heat Shock Proteins and Diseases
Section 3‐10: Metabolic Signalling and Disease
Section 3‐11: Amyloids and Disease

Chapter 4: Proteins Therapeutics and Clinical Significance
Section 4‐1: Protein Drug Discovery Technology
Session 4‐1‐1: Discovery of Emerging Protein Therapeutic Targets  
Session 4‐1‐2: Protein Structure, Modeling, and Fragment‐based Drug Discovery
Session 4‐1‐3: Design Drugs Targeting Protein‐protein Interactions
Session 4‐1‐4: Transmembrane and Fusion Proteins Based Drug Discovery
Session 4‐1‐5: Protein Surface Recognition Approaches for Drug Discovery
Session 4‐1‐6: Plasma Protein Therapeutics  
Session 4‐1‐7: Anticancer Protein Therapeutics
Session 4‐1‐8: Protein Therapeutics for Immunologic & Inflammatory Diseases
Session 4‐1‐9: DMPK and ADMET of Protein Drugs
Section 4‐2: Protein Biomarkers  
Session 4‐2‐1: Protein Biomarker Discovery and Validation for Diagnosis and Treatment  
Session 4‐2‐2: Toxicity Biomarkers and Biomarkers Assay Development
Session 4‐2‐3: Protein Biomarkers for Cancers
Session 4‐2‐4: Protein Biomarkers for Diseases:
Cardiovascular, CNS, Inflammation and Immunology
Session 4‐2‐5: Protein Biomarkers for Personalized
Medicine
Section 4‐3: Cytokines  
Session 4‐3‐1: New Landscape of Cytokine Drug Discovery
from Targets/Receptors to Screening Assays  
Session 4‐3‐2: Novel Drugs Targeting Cytokine Storm  
Session 4‐3‐3: Cancer Drug Discovery Targeting Cytokine in the Genesis
Session 4‐3‐4: Cytokine Receptors and Implications
Session 4‐3‐5: Anti‐inflammatory Cytokine Antagonists
Session 4‐3‐6: Plasma Cytokines, Diseases and Diagnosis
Session 4‐3‐7: Cysteine‐knote Cytokines
Section 4‐4: Kinases
Session 4‐4‐1: Kinase Structure, Signaling Pathways,
Network and Selectivity
Session 4‐4‐2: Computer Aided and Structure Based Kinase Drug Design
Session 4‐4‐3: Oncology, Inflammation & Autoimmune
Kinase Inhibitors
Session 4‐4‐4: Drugs Targeting PI3‐Kinases, and AKT/MAP Kinase
Session 4‐4‐5: Protein Kinase CK2
Session 4‐4‐6: Kinases for CNS Indications
Session 4‐4‐7: Screening& Monitoring DMPK and Tox of  Kinase Inhibitors
Session 4‐4‐8: Overcome Drug‐resistant Kinase Inhibitors
Section 4‐5: NF‐kB based Drug Discovery and Clinical Significance
Session 4‐5‐1: Structure and Molecular Basis of NF‐kB
Session 4‐5‐2: NF‐κB Signaling Pathway and Regulations  
Session 4‐5‐3: NF‐κB as Drug Targets of Immunological Diseases  
Session 4‐5‐4: NF‐κB as Drug Targets of CNS & Neurological Disorders
Session 4‐5‐5: Anticancer Drugs Targeting NF‐κB
Session 4‐5‐6: Anti‐inflammatory Drug Discovery Targeting NF‐kB
Session 4‐5‐7: NF‐kB based Drug Resistant Antibiotic Discovery  
Session 4‐5‐8: Gene Therapy Targeting NF‐kB
Session 4‐5‐9: NF‐κB to Chronic Liver Disease
Session 4‐5‐10: NF‐κB as Biomarkers and Molecular Diagnosis
Section 4‐6: Protein Therapeutics Formulation and Delivery
Session 4‐6‐1: How to Overcome Protein Degradations for Longer Half‐life
Session 4‐6‐2: PEGylated Protein Drugs
Session 4‐6‐3: Methods Improving the Quality of Protein Formulation  
Session 4‐6‐4: Transdermal Protein Delivery Technology  
Session 4‐6‐5: Oral and Nasal Protein Delivery Technology  
Session 4‐6‐6: Pulmonary Protein Delivery Technology  
Session 4‐6‐7: Medical Devices for Protein Drug Delivery  
Session 4‐6‐8: Optimizing Biologics Formulation and Industrial Process
Session 4‐6‐9: Formulated Protein Characterization and QA/QC

Chapter 5: Non ‐ Human Protein R & D

Section 5‐1: Non‐human Proteins and Pathogenesis
Section 5‐2: Non‐human Proteins and Food Security
Section 5‐3: Animal Proteins
Section 5‐4: Insect Proteins
Section 5‐5: Plant Proteins and Engineering
Section 5‐6: Crop Proteins
Section 5‐7: Fish Proteins
Section 5‐8: Marine Proteins
Section 5‐9: Natural Proteins and Recombinant Technology
Section 5‐10: Protein as Biomaterials 

Part 2: Peptide Chemistry and Biology

Chapter 6: Peptide Science

Section 6‐1: Peptides Identification and Biological Function Assay  
Section 6‐2: Peptide Structural Studies
Section 6‐3: Self‐assembling Peptide Systems
Section 6‐4: Signaling Peptides and Implications  
Section 6‐5: Peptides Surface Binding and Peptide‐Protein Interactions
Section 6‐6: Peptide Biomarkers
Section 6‐7: Selective Peptide‐based Reporters
Section 6‐8: Peptide Transporters and Trafficking
Section 6‐9: Ribosomal Peptides
Section 6‐10: Membrane‐Active Peptides  
Section 6‐11: Peptide Nucleic Acids, Peptide Aptamers and Encoded Libraries
Section 6‐12: Lipo/Glyco/Phospho/Sulpho Peptides
Section 6‐13: Peptide Microarrays and Applications  
Section 6‐14: Peptide Nanotechnology and Peptide‐coated Quantum Dots
Section 6‐15: Cell and Peptide Engineering

Chapter 7: Peptide Chemistry and Synthetic Methods

Section 7‐1: Organization and Structural Studies of Peptide Motifs
Section 7‐2: Gene Expression and Production of Antimicrobial Peptides
Section 7‐3: Nanoscale Peptide Scaffolds Mimicking
Section 7‐4: Mixture‐based Combinatorial Libraries and Solid Phase Synthesis
Section 7‐5: Peptide Synthesis by Sequential Multicomponent Reactions
Section 7‐6: Practical Microwave Synthesis of Peptides
Section 7‐7: Synthesis and Analytics of Rigidified Peptide Architectures
Section 7‐8: Synthesis of Peptoid‐containing Macrocycles and Podands
Section 7‐9: Enzymatic Peptide Synthesis
 
Chapter 8: Peptides in Drug Discovery
 
Section 8‐1: Peptidomimetics Based Drug Design and Pseudo‐peptides in Drug Discovery
Section 8‐2: Peptide‐based Receptors
Section 8‐3: Bioactive Natural Peptide Products Based Drug Discovery
Section 8‐4: Enzymes Substrates and Peptide Inhibitors
Section 8‐5: Peptide Drug Delivery Technology
Section 8‐6: Peptide‐targeted Radiotherapy of Cancer
Section 8‐7: Anticancer Peptides against Major Cancers
Section 8‐8: Antibecterial Peptides
Section 8‐9: Antifungal Peptides
Section 8‐10: Antiviral Peptides
Section 8‐11: Synthetic Peptides as Antigens and Peptide‐based Vaccines
Section 8‐12: Peptide Mimetic Diabetic Drug
 
Chapter 9: Explorations on Biologically Active Peptides and Applications
 
Section 9‐1: Peptide Hormones
Section 9‐2: Immunological and Inflammatory Peptides
Section 9‐3: Brain Peptides  
Section 9‐4: Cardiovascular Peptides  
Section 9‐5: Endocrine Peptides
Section 9‐6: Ingestive and Gastrointestinal Peptides
Section 9‐7: Renal Peptides
Section 9‐8: Neurotrophic Peptides
Section 9‐9: Opioid Peptides
Section 9‐10: Respiratory Peptides
Section 9‐11: Blood‐brain Barrier Peptides
Section 9‐12: Plant Peptides
Section 9‐13: Amphibian Peptides
Section 9‐14: Invertebrate Peptides
Section 9‐15: Venom Peptides
 
Chapter 10: Emerging Applications of Peptides
Section 10‐1: Pheromone Peptides and Peptide Hormones  
Section 10‐2: Fish Peptides
Section 10‐3: Peptides, Sleep and Chronomics
Section 10‐4: Prebiotic Peptides and Applications
Section 10‐5: Peptides in Agricultural and Aquacultural Applications
Section 10‐6: Peptides for Veterinary Applications
Section 10‐7: Peptide as Organocatalysts
Section 10‐8: Peptide Biomaterials and Applications
Section 10‐9: Peptides as Biosurfactants
Section 10‐10: Artificial Metal Peptides, and Seleno‐peptides

Part 3: Protein Industry

Chapter 11: Protein Engineering Technology
Section 11‐1: Design and Computation for Protein Bioprocessing
Section 11‐2: Improved Protein Expression Systems
Section 11‐3: Evolutionary Strategies for Protein Engineering
Section 11‐4: CHO Platforms for Proteins
Section 11‐5: High Throughput Protein Expression and Purification  
Section 11‐6: Biosynthetic Pathway Engineering for Protein Production
Section 11‐7: Challenging Mammalian Expression and Membrane Proteins
Section 11‐8: Protein Engineering by Phage Display
Section 11‐9: Cell Culture and Upstream Process Development
Section 11‐10: Cell Free Technologies for Proteins
Section 11‐11: Scaling up Bioprocess Development for Biotherapeutics
Section 11‐12: Protein Separation and Purification Technologies
Section 11‐13: Improved Separation, Recovery, Crystallization, and Lyophilization
Section 11‐14: Case Study on Expression of Soluble Proteins
Section 11‐15: Case Study on Expression of Difficult Proteins
 
Chapter 12: Innovative Instrument and Equipment
Section 12‐1: Fermentation Equipment, and Single‐use / Disposable Bio‐processing Equipment
Section 12‐2: Tag Technologies in Biomanufacturing
Section 12‐3: Optimizing and Automating Protein Engineering
Section 12‐4: Chromatography Technology for Protein Purification
Section 12‐5: Removal and Analysis of Contaminants and Impurities
Section 12‐6: cGMP Facilities for Production of Recombinant Proteins
 
Chapter 13: Protein QC/QA and Analytic Tools
Section 13‐1: Protein Immunogenicity Assessment in Drug Discovery and Development  
Section 13‐2: Chip and Microarray Technology for Protein Analysis
Section 13‐3: HPLC, LC‐MS and SFC in Protein Analysis
Section 13‐4: PAT and GMP Compliance Analytical Technologies
Section 13‐5: Flow Cytometry and Microorganism Display in Protein Quantification  

Part 4: Protein and Peptide Business and Market
Chapter 14: Protein/Peptide CRO/CMO and Business Development
Section 14‐1: Protein and Peptide CRO Strategies
Section 14‐2: CMO for Peptide and Protein Therapeutics
Section 14‐3: Protein/Peptide Technology Transfer, Business Development and IP Protection
Section 14‐4: Capacity Analysis of Protein/Peptide Vendors
Section 14‐5: Peptide Reagents and Synthetic Methodology Development
 
We are now calling for chairs, co‐chairs and Presentation of PepCon‐2012!
Join us by submit your Presentation Topics and Scientific and Technological Posters!
Please contacting Us: Sally Guo, sally@bitlifesciences.com , Tel: 0086‐411‐84799609‐801
 
Who Should Exhibit?
    •   Protein Therapeutics  
    •   Protein/Peptide Drug
    •   Peptide Synthesis  
    •   Protein Chips and Microarrays  
    •   Protein Characterization  
    •   Enzyme Engineering  
    •   Custom Peptide
    •   Antibody Engineering  
    •   Vaccine  
    •   Bioinformatics  
    •   Bioprocess
    •   CRO  
    •   Drug Discovery
    •   Biomarkers  
    •   Diagnostics   
    •   Scale‐Up & High‐throughput  
    •   Purification & Sequencing  
    •   Expression Vectors  
    •   Drug Delivery  
    •   Immunogenicity  
    •   Assay Development  
    •   Disease Prognosis
    •   Nanotechnology
    •   Peptide Therapeutics
    •   Bioactive Peptides
    •   Formulation Technologies
    •   Insulin & Interferon
    •   Software & Solution
 
Exhibition and Poster
 
PepCon‐2012 provides a unique place for leading biotechnology companies, institutions and general suppliers of equipment and consumables to exhibit their products, technologies and services to a captive audience. Up to 100 leading companies will be able to reach an international community of 1000 leading researchers, biotechnology and pharmaceutical executives, and technology transfer and service providers at PepCon‐2012.
          
Why Reserve a Booth at PepCon‐2012  
    •   Meet face to face with key leaders in the field of protein and peptide science and technology 
    •   Meet with key decision makers from around the world 
    •   Maintain your competitive advantage within the scientific community
    •   Explore new business opportunities both at home and abroad  
    •   Spotlight  your  advanced  technologies  and  their  scientific  and commercial applications  
    •   Receive discounts on conference registration
    •   Access to the post‐event mailing list through a third party vendor 
    •   BIT will conduct marketing campaigns to promote your participation
 
Exhibits Ranges:
 
1.  Analyzing Testing Instrument: analytical instrument and equipment, optical spectrum instrument, chromatographic apparatus, mass spectrograph instrument, frequency spectrum equipment, spectrum instrument, optic analytical instrument, thermal‐analysis instrumentation surface analytical instrument, elementary analysis instrument,
ingredient analysis instrument, procedure analysis instrument, graphical analysis instrument, ray analysis instrument, gas phase chromatography, liquid chromatogram, microscope, optics image processing etc.
 
2.  Life Science Instrument: polypeptide combiner, amino acid tester, DNA combiner, diagnosis instrument, biological biochemistry instrument, biological incubator, fermentation cylinder, alias a, biosensor, biological engineering process control and processing technique equipment.
 
3.  Laboratory instrument and equipment: heat system, reaction equipment, dose weighing system, automation equipment, independent technique, laboratory furniture, laboratory supply, laboratory armamentarium, laboratory data system, laboratory graphical analysis and process, laboratory techniques and instrument, conveying equipment
and connection device, cleaning, drying plant, cleaner environment engineering equipment est.
 
4.  Technique and Service: polypeptide compound, outsourcing service, synthesis of amino acids, medicine research and development, biological product, vaccine and antibody, biology information technology, biological label, biological reagent, protein chip and microarray, protein treatment, enzyme engineering, purify sequencing, medicine release,
enlarge manufacture, all kinds of reagent, raw material, mid‐body, software product, information and services etc.
 
For details please check: http://www.bitlifesciences.com/pepcon2012/exhibition.asp or contact the mailbox of our coordinator jason@bitlifesciences.com  
 
About PepCon: The Dedicated Event for Protein/Peptide Professionals is marching into updating current frontier and advances in Protein/Peptide Sciences and Technology along with good business potentials. We will invite both Academic and Industrial leaders from around the world to discuss the latest research and developments and breakthroughs in understanding the essence of life and its functions to enhanced applications in Bio‐Economic Era.

PepCon’s philosophy is to “Let Professionals Help Professionals”. PepCon is your stage to publish your visualized achievements annually and share your excitement, passion, creativity and innovation by networking with our colleagues in protein and peptide society.
The 1st Annual Protein and Peptide Conference (PepCon‐2008), held in Shenzhen Convention & Exhibition Center from April 22‐24, 2008. It attracted international experts and professors from 31 countries to attend actively and contribute greatly which made it an impressive and influential conference.
 
The 2nd Annual Protein and Peptide Conference (PepCon‐2009), held in the COEX Convention & Exhibition Center in Seoul, South Korea from April 2‐4, 2009 was an
overwhelming success. The theme of the conference was “Life, Knowledge & Bio‐Economy.”
 
The 3rd Annual Protein and Peptide Conference (PepCon‐2010) was held successfully form March 21‐23, 2010 in the Beijing International Convention Center, China. The theme of the conference was “After a Solution for the Machines of Life.” Over 600 participants from more than 30 countries attended the 3 day conference.
 
The 4th Annual Protein and Peptide Conference (PepCon‐2011), held in China National Convention Center, Beijing, China from March 23‐25, 2011 has gained great success. The theme of the conference was “New Leaders in Protein and Peptide Science. More than 800 experts and industrial leaders from 36 countries attended this conference and 60 companies exhibited their products and technologies.
Contact Us:

Organizing Committee of PepCon‐2012

Ms. Sally Guo,
Tel: 0086‐411‐8479609‐801
Fax: 0086‐411‐84799629,
E‐mail:
sally@bitlifesciences.com

Add: F11, Building 1, 1 Hui Xian Yuan,
Dalian Hi‐tech Industrial Zone,
LN 116025, China

Website:
http://www.bitlifesciences.com/pepcon2012/